Vitamin E is a fat-soluble nutrient whose principal biologically active form is alpha-tocopherol. It is essential for protection of lipid-rich cell membranes and is used to correct deficiency. Veterinary applications include nutritional myodegeneration and selected equine neurologic disorders, with separate adjunctive uses in some hepatic or dermatologic diseases.
Group
Fat-soluble antioxidant vitamin
Mechanism of Action
Alpha-tocopherol donates a hydrogen atom to lipid radicals and interrupts propagation of membrane lipid peroxidation. This limits oxidative injury to muscle, nervous tissue and other lipid-rich structures. It works alongside other antioxidant systems, including selenium-dependent enzymes. Replacement restores antioxidant protection in deficient animals, while the clinical effect in other diseases depends on their pathogenesis.
Dose Rates
Dogs
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Antioxidant supplementation | 100–400 IU/animal | PO | Every 12 h | |
| Immune-mediated skin disease adjunct | 400–600 IU/animal | PO | Every 12 h | Evidence for dermatologic benefit is limited and variable. |
| Hepatopathy adjunct | 10–15 IU/kg | PO | Every 24 h | |
| Discoid lupus adjunct | 200–400 IU/animal | PO | Every 12 h | |
| Copper-associated hepatopathy adjunct | 400–600 IU/animal | PO | Every 24 h | |
| Exocrine pancreatic disease-associated deficiency — Initial | 100–400 IU/animal | PO | Every 24 h | Up to 30 days; Thereafter the source describes dosing every 1-2 weeks as needed. |
Cats
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Antioxidant supplementation | 100–400 IU/animal | PO | Every 12 h | |
| Immune-mediated skin disease adjunct | 400–600 IU/animal | PO | Every 12 h | Evidence for dermatologic benefit is limited and variable. |
| Hepatopathy adjunct | 10–15 IU/kg | PO | Every 24 h | |
| Exocrine pancreatic disease-associated deficiency — Initial | 30 IU/animal | PO | Every 24 h | Up to 30 days; Thereafter every 1-2 weeks as needed. |
| Hepatic lipidosis adjunct | 10 IU/kg | PO | Every 24 h |
Horses
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Ionophore poisoning adjunct | 4–12 IU/kg | PO | Every 24 h | Adjunct only, not an antidote. |
| EPM adjunct | 8000–9000 IU/animal | PO | Every 24 h | Does not replace antiprotozoal treatment. |
| Metabolic syndrome adjunct | 10000 IU/animal | PO | Every 24 h | Historical adjunct; response evidence is limited. |
| Perinatal asphyxia adjunct - foal | 4000 IU/animal | PO | Every 24 h | Foals only. |
| Perinatal asphyxia adjunct - mare | 10000 IU/animal | PO | Every 24 h | Maternal adjunct regimen. |
Cattle
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Vitamin E supplementation | 2400–3000 IU/animal | IM | Once | Adult cattle; source allows reassessment/repetition in 2-3 months. |
| Vitamin E supplementation - calf | 1200–1800 IU/animal | IM | Once | Calves only; source allows reassessment/repetition in 2-3 months. |
Sheep
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Vitamin E supplementation | 1200–1800 IU/animal | IM | Once | Reassess need in 2-3 months. |
Pigs
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Vitamin E supplementation | 1200–1800 IU/animal | IM | Once | Reassess need in 2-3 months. |
Indications
- Treatment or prevention of vitamin E deficiency in veterinary patients.
- Treatment of nutritional myodegeneration in calves, lambs, foals or other susceptible species, with accompanying deficiencies addressed in the overall plan.
- Replacement in vitamin-E-deficient horses with equine motor neuron disease or compatible nutritional neurologic disease, with response dependent on established injury.
- Adjunctive supplementation in selected canine hepatopathies or immune-mediated dermatoses, with limited disease-specific outcome evidence.
Contraindications
- Use cautiously in coagulopathy; selenium-containing products have additional species-specific toxicity constraints.
Interactions
- May enhance anticoagulant effects of warfarin.
- Mineral oil can reduce oral absorption.
Adverse effects
- Excessive doses can impair coagulation; injectable combinations may cause hypersensitivity.
Toxicity
Stop excess dosing and evaluate coagulation. Selenium toxicity must be assessed separately after combination-product overdose.
Preparations
| Preparation | Form | Strength | Route |
|---|---|---|---|
| Alpha-tocopherol oral capsules 400 IU Use an IU-labelled product; no mg-equivalence or selenium content is inferred. | Capsule | 400 IU / capsule | PO |
Monitoring and Administration
IU-to-mg conversion depends on chemical form and stereoisomer composition; do not apply one conversion to every alpha-tocopherol product.
Use IU when the source and product are IU-labelled. Do not add selenium to achieve a vitamin E dose without a separate selenium calculation.
Monitor clinical response and bleeding; assess serum alpha-tocopherol when deficiency is suspected.